Abstract:Mycobacterium tuberculosis remains a significant threat to global health. Macrophages are the host cell for M. tuberculosis infection, and although bacteria are able to replicate intracellularly under certain conditions, it is also clear that macrophages are capable of killing M. tuberculosis if appropriately activated. The outcome of infection is determined at least in part by the host-pathogen interaction within the macrophage; however, we lack a complete understanding of which host pathways are critical for bacterial survival and replication. To add to our understanding of the molecular processes involved in intracellular infection, we performed a chemical screen using a high-content microscopic assay to identify small molecules that restrict mycobacterial growth in macrophages by targeting host functions and pathways. The identified host-targeted inhibitors restrict bacterial growth exclusively in the context of macrophage infection and predominantly fall into five categories: G-protein coupled receptor modulators, ion channel inhibitors, membrane transport proteins, anti-inflammatories, and kinase modulators. We found that fluoxetine, a selective serotonin reuptake inhibitor, enhances secretion of pro-inflammatory cytokine TNF-α and induces autophagy in infected macrophages, and gefitinib, an inhibitor of the Epidermal Growth Factor Receptor (EGFR), also activates autophagy and restricts growth. We demonstrate that during infection signaling through EGFR activates a p38 MAPK signaling pathway that prevents macrophages from effectively responding to infection. Inhibition of this pathway using gefitinib during in vivo infection reduces growth of M. tuberculosis in the lungs of infected mice. Our results support the concept that screening for inhibitors using intracellular models results in the identification of tool compounds for probing pathways during in vivo infection and may also result in the identification of new anti-tuberculosis agents that work by modulating host pathways. Given the existing experience with some of our identified compounds for other therapeutic indications, further clinically-directed study of these compounds is merited.

A selective PPM1A inhibitor activates autophagy to restrict the survival of Mycobacterium tuberculosis

SMIP-30, a Potent and Selective PPM1A Inhibitor with Potential to Treat Tuberculosis

Small Molecule Targeting PPM1A Activates Autophagy for Mycobacterium tuberculosis Host-Directed Therapy

Highly Potent and Selective N-Aryl Oxamic Acid-Based Inhibitors for Mycobacterium Tuberculosis Protein Tyrosine Phosphatase B

Structure-Based Screening and Optimization of PafA Inhibitors with Potent Anti-Tuberculosis Activity

Discovery and Mechanistic Study of Mycobacterium Tuberculosis PafA Inhibitors

Discovery of uncompetitive inhibitors of SapM that compromise intracellular survival of Mycobacterium tuberculosis

PP2Ac Modulates AMPK-Mediated Induction of Autophagy in Mycobacterium Bovis-Infected Macrophages.

[Advances in the Study of Mycobacterium Tuberculosis Protein Phosphatase and Its Inhibitors].

Mycobacterium tuberculosis inhibition of phagolysosome biogenesis and autophagy as a host defence mechanism

Targeted protein degradation in mycobacteria uncovers antibacterial effects and potentiates antibiotic efficacy

Identification of Host-Targeted Small Molecules That Restrict Intracellular Mycobacterium tuberculosis Growth

MpbR, an essential transcriptional factor for Mycobacterium tuberculosis survival in the host, modulates PIM biosynthesis and reduces innate immune responses.

Docking- and Pharmacophore-Based Virtual Screening for the Identification of Novel Mycobacterium Tuberculosis Protein Tyrosine Phosphatase B (mptpb) Inhibitor with a Thiobarbiturate Scaffold

Myeloid-Derived Suppressor Cells as Target of Phosphodiesterase-5 Inhibitors in Host-Directed Therapeutics for Tuberculosis

Repurposing diphenylbutylpiperidine-class antipsychotic drugs for host-directed therapy of Mycobacterium tuberculosis and Salmonella enterica infections

<i>Mycobacterial</i> PPE36 Modulates Host Inflammation by Promoting E3 Ligase Smurf1-Mediated MyD88 Degradation

Dual-targeting GroEL/ES chaperonin and protein tyrosine phosphatase B (PtpB) inhibitors: A polypharmacology strategy for treating Mycobacterium tuberculosis infections

Opposing reactions in coenzyme A metabolism sensitize Mycobacterium tuberculosis to enzyme inhibition

Mycobacteria Tuberculosis PPE36 Modulates Host Inflammation by Promoting E3 Ligase Smurf1-mediated MyD88 Degradation

Double Click Reaction for the Acquisition of a Highly Potent and Selective Mptpb Inhibitor